Text Di

Let’s get into facts behind Ozempic, the GLP-1 receptor agonist making waves in the health community. We're diving into the science that enables Ozempic to mimic a natural hormone, effectively regulating blood sugar and curbing appetite. From enhancing insulin secretion to delaying gastric emptying, discover the multifaceted approach this medication takes to tackle weight and diabetes. 

We'll dissect groundbreaking studies, including a 2021 New England Journal of Medicine landmark study, that highlight Ozempic's impressive results—like an average weight loss of nearly 15% among participants. With insights from the SUSTAIN trials, we'll explore how it outperforms other diabetes medications in managing type 2 diabetes and improving A1C levels. Promising long-term effectiveness, Ozempic stands out as a powerhouse for enhancing metabolic health. Tune in as we debunk the myths, offer real-world strategies, and provide a clear-eyed look at Ozempic.

Weight Loss Studies:

• Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002.   
• Wilding, J. P. H., et al. (2021). Weight Loss and Cardiometabolic Health with Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 1003–1015.
• Davies, M., et al. (2023). Two-Year Effects of Semaglutide in Adults with Overweight or Obesity: The STEP 5 Trial. Diabetes, Obesity and Metabolism, 25(1), 109–120.

Blood Sugar Control Studies (SUSTAIN Trials):

• Ahmann, A. J., et al. (2018). Efficacy and Safety of Once-Weekly Semaglutide Versus Sitagliptin as an Add-on to Metformin, Thiazolidinediones, or Both, in Patients with Type 2 Diabetes (SUSTAIN 2): a Randomised, Double-blind, Placebo-controlled, Phase 3a Trial. The Lancet Diabetes & Endocrinology, 6(4), 251–260.
• Marso, S. P., et al. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine, 375(19), 1834–1844. (This is the SUSTAIN 6 trial, which also looked at cardiovascular outcomes)   

Cardiovascular Risk Reduction Study (SELECT Trial):

• Husain, M., et al. (2023). Semaglutide and Cardiovascular Outcomes in Patients with Overweight or Obesity. New England Journal of Medicine, 388(15), 1374–1386.

Support the show

You can find the workouts and online community here: https://www.bodyholic.fit
Please consider following Bodyholic on Instagram for more information.

Music is

Urban Traffic Hip Hop
By Trending Music

Photo by Boris Kuznetz